HK1170809A1 - Use of 2 anti-sparc antibodies to predict response to chemotherapy sparc - Google Patents

Use of 2 anti-sparc antibodies to predict response to chemotherapy sparc

Info

Publication number
HK1170809A1
HK1170809A1 HK12111585.4A HK12111585A HK1170809A1 HK 1170809 A1 HK1170809 A1 HK 1170809A1 HK 12111585 A HK12111585 A HK 12111585A HK 1170809 A1 HK1170809 A1 HK 1170809A1
Authority
HK
Hong Kong
Prior art keywords
sparc
chemotherapy
antibodies
predict response
predict
Prior art date
Application number
HK12111585.4A
Other languages
English (en)
Chinese (zh)
Inventor
．德留
．德賽
．瑙爾
Original Assignee
阿布拉西斯生物科學有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 阿布拉西斯生物科學有限責任公司 filed Critical 阿布拉西斯生物科學有限責任公司
Publication of HK1170809A1 publication Critical patent/HK1170809A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK12111585.4A 2009-05-28 2012-11-15 Use of 2 anti-sparc antibodies to predict response to chemotherapy sparc HK1170809A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18208109P 2009-05-28 2009-05-28
PCT/US2010/036615 WO2010138839A2 (fr) 2009-05-28 2010-05-28 Utilisation de 2 anticorps anti-sparc en vue de prévoir la réaction à une chimiothérapie

Publications (1)

Publication Number Publication Date
HK1170809A1 true HK1170809A1 (en) 2013-03-08

Family

ID=43223381

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12111585.4A HK1170809A1 (en) 2009-05-28 2012-11-15 Use of 2 anti-sparc antibodies to predict response to chemotherapy sparc

Country Status (14)

Country Link
US (2) US8383358B2 (fr)
EP (1) EP2435068B1 (fr)
JP (1) JP5886191B2 (fr)
KR (1) KR20120024794A (fr)
CN (1) CN102460168B (fr)
AU (1) AU2010253747B2 (fr)
BR (1) BRPI1014392A2 (fr)
CA (3) CA2853810C (fr)
ES (1) ES2533343T3 (fr)
HK (1) HK1170809A1 (fr)
IL (1) IL216580A (fr)
MX (1) MX2011012657A (fr)
WO (1) WO2010138839A2 (fr)
ZA (1) ZA201108999B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2792667A1 (fr) * 2010-03-11 2011-09-15 Abraxis Bioscience, Llc Domaine angiogenique sparc et procedes d'utilisation
CA2801190A1 (fr) 2010-06-03 2011-12-08 Abraxis Bioscience, Llc Utilisation de la signature du microenvironnement des sparc dans le traitement du cancer
US9511046B2 (en) * 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
CN111066727B (zh) * 2019-12-20 2021-08-27 中国人民解放军陆军军医大学 在低氧性血睾屏障通透中作用机制的小鼠模型构建方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5003621A (en) * 1989-11-02 1991-03-26 Motorola, Inc. Direct conversion FM receiver
DE69233254T2 (de) * 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
ES2565327T3 (es) 2003-01-14 2016-04-04 Dana Farber Cancer Institute Sensibilizador de terapia del cáncer
EP1644530A4 (fr) * 2003-06-24 2006-10-04 Univ Johns Hopkins Biomarqueurs geniques methyles servant a detecter le cancer
CN105316405A (zh) * 2003-07-17 2016-02-10 环太平洋生物技术有限公司 用于胃癌检测的标记物
AU2006249235B2 (en) * 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
GB0417740D0 (en) * 2004-08-10 2004-09-08 Uc3 Methods and kit for the prognosis of breast cancer
US20100069298A1 (en) 2008-09-16 2010-03-18 Robert Penny Methods for Detecting Overexpression of SPARC and Therapeutic and Diagnostic Methods Relating to Same
CN102576016A (zh) 2009-09-18 2012-07-11 阿布拉西斯生物科学有限责任公司 Sparc微环境标签在癌症治疗中的应用

Also Published As

Publication number Publication date
CN102460168A (zh) 2012-05-16
CA2853810A1 (fr) 2010-12-02
CA2853810C (fr) 2017-04-25
WO2010138839A3 (fr) 2011-03-03
BRPI1014392A2 (pt) 2016-04-05
US20130172261A1 (en) 2013-07-04
CN102460168B (zh) 2015-05-20
KR20120024794A (ko) 2012-03-14
US9091697B2 (en) 2015-07-28
IL216580A (en) 2015-11-30
EP2435068B1 (fr) 2015-03-04
ZA201108999B (en) 2013-05-29
US20100310507A1 (en) 2010-12-09
WO2010138839A2 (fr) 2010-12-02
CA2763950C (fr) 2015-11-24
ES2533343T3 (es) 2015-04-09
JP5886191B2 (ja) 2016-03-16
WO2010138839A9 (fr) 2011-01-13
AU2010253747A1 (en) 2011-12-15
IL216580A0 (en) 2012-02-29
US8383358B2 (en) 2013-02-26
AU2010253747B2 (en) 2013-07-11
MX2011012657A (es) 2012-01-12
CA2763950A1 (fr) 2010-12-02
CA2960887A1 (fr) 2010-12-02
EP2435068A4 (fr) 2013-03-27
JP2012528337A (ja) 2012-11-12
CA2960887C (fr) 2018-09-04
EP2435068A2 (fr) 2012-04-04

Similar Documents

Publication Publication Date Title
IL255300A0 (en) Antibodies to matrix metalloproteinase 9 (mmp9)
EP2504031A4 (fr) Anticorps anti-il-6 et leur utilisation
IL232276A0 (en) Antibodies to 6-il and their uses
HK1217711A1 (zh) 特異於鈣粘素- 的抗體
IL216085A0 (en) Selective access to cryopreserved samples
IL214779A0 (en) Fully human antibodies specific to cadm1
EP2125890A4 (fr) Anticorps contre l'irak4 phosphorylé
EP2212431A4 (fr) Anticorps anti-irem-1
EP2582628A4 (fr) Synthèse sans alcalins de matériaux zéolitiques de structure de type lev
HK1201578A1 (en) Improvements in or relating to reading of assays
HK1170809A1 (en) Use of 2 anti-sparc antibodies to predict response to chemotherapy sparc
IL216444A (en) Chemo-enzymatic approach to the synthesis of pimcrolimus
TWM370966U (en) Structure of travel backpack
TWM370683U (en) Improved counter weight structure of pipe
TWM401082U (en) Improved structure of faucet to swing vertically
TH129814B (th) แอนติบอดีต่อ nr10 และการใช้ประโยชน์ของมัน
TWM373987U (en) Structural improvement of faucet
PL390096A1 (pl) Zastosowanie olejku eterycznego do zwalczania roztoczy
PL390098A1 (pl) Zastosowanie olejku eterycznego do zwalczania roztoczy
TWM401724U (en) Improved structure of faucet with dual temperatures

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190527